Antidepressant Efficacy and Risk of Suicidality

Antidepressant medications are a cornerstone in the management of depressive disorders and other mood disturbances, demonstrating clear benefits in symptom remission, functional recovery and reduction of relapse. Efficacy varies by class and individual agent, with selective serotonin reuptake inhibitors (SSRIs) often preferred for their tolerability and safety profile. Nonetheless, concerns persist regarding the emergence or worsening of suicidal ideation, particularly in younger populations during the early phases of treatment. Regulatory agencies have issued warnings to guide clinical vigilance, and meta-analyses of randomised trials and observational cohorts have yielded nuanced findings: while some studies report an initial increase in self-harm risk among adolescents and young adults, others indicate a net reduction in suicidal behaviour once therapeutic levels are achieved. The balance of benefits and risks underscores the importance of comprehensive assessment, close monitoring during treatment initiation, and integration of pharmacotherapy with psychosocial support. Research has further highlighted age-related differences, suggesting that the risk-benefit ratio shifts across the lifespan and that combined interventions—medication plus psychotherapy—may mitigate adverse outcomes. From a public-health perspective, ensuring access to effective antidepressant treatment while maintaining safeguards against treatment-emergent suicidality remains a global priority, demanding ongoing refinement of prescribing guidelines and patient education.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antidepressant Efficacy and Risk of Suicidality publication trend

The graph below shows the total number of articles in antidepressant efficacy and risk of suicidality across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitor (SSRI): A class of antidepressants that increase serotonin levels in the brain by blocking its reabsorption into nerve cells, reducing depressive symptoms and improving mood.

Target trial emulation: A methodological approach in observational research that mimics the design of a randomised trial to estimate causal effects by specifying eligibility criteria, treatment strategies and follow-up periods.

Within-individual design: A study framework in which each participant serves as their own control, comparing risk periods before and after exposure to assess treatment-related changes in outcomes.

References

1. Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation. Neuropsychopharmacology (2023).
2. An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide - A Nationwide Register-Based Case-Crossover Study. PLOS ONE (2013).
3. Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies. Frontiers in Psychiatry (2022).
4. Is combined antidepressant medication (ADM) and psychotherapy better than either monotherapy at preventing suicide attempts and other psychiatric serious adverse events for depressed patients? A rare events meta-analysis.. Psychological Medicine (2023).